Clarius Group Portfolio holdings
Clarius Group is a multi-family office that serves ultra-high-net-worth individuals and families. It provides investment advice, family office services and personal accounting. Keith Vernon and Matthew Talbot are among its founding partners. Clearstead Advisors, an investment adviser, bought the firm in a deal that closed in January 2026.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
APTI
Apptio, Inc. Class A Common Stock
APTI
|
+$1.53M |
| 2 |
Renasant Corp
RNST
|
+$734K |
| 3 |
iShares National Muni Bond ETF
MUB
|
+$236K |
| 4 |
bluebird bio
BLUE
|
+$207K |
| 5 |
Expeditors International
EXPD
|
+$196K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sage Therapeutics
SAGE
|
+$8.04M |
| 2 |
Agios Pharmaceuticals
AGIO
|
+$7.29M |
| 3 |
Amazon
AMZN
|
+$4.07M |
| 4 |
Editas Medicine
EDIT
|
+$2.09M |
| 5 |
State Street SPDR Bloomberg Short Term High Yield Bond ETF
SJNK
|
+$1.86M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 39.94% |
| 2 | Miscellaneous | 28.99% |
| 3 | Consumer Discretionary | 15.84% |
| 4 | Technology | 5.9% |
| 5 | Communication Services | 4.2% |
Similar funds
Clarius Group's Q4 2017 Portfolio in Review
As of Q4 2017, Clarius Group held 77 positions worth $224M, down 5.7% from $238M the previous quarter. Its ten largest holdings account for 76% of the portfolio.
Clarius Group withdrew a net $22M in Q4 2017, closing 10 positions and reducing 15 holdings. Its most notable exit was Sage Therapeutics, an estimated $8.04M position sold in full.
By sector, the portfolio is most concentrated in Industrials at 40% of assets, up from 38% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.
Against the trend, Clarius Group opened a new position in Apptio, Inc. Class A Common Stock worth $1.7M.
- Clarius Group's largest Q4 2017 buy was Apptio, Inc. Class A Common Stock: 72,206 shares worth $1.7M.
- Clarius Group added most to iShares National Muni Bond ETF in Q4 2017, an estimated $236K increase.
- Clarius Group's biggest Q4 2017 reduction was Amazon, cutting an estimated $4.07M.
- Clarius Group fully exited Sage Therapeutics in Q4 2017, selling an estimated $8.04M.
- Clarius Group's ten largest holdings make up 76% of its $224M portfolio in Q4 2017.
- Clarius Group opened 7 new positions and closed 10 in Q4 2017.
- Clarius Group's portfolio value fell 5.7% quarter-over-quarter to $224M.
Based on Clarius Group's 13F filing for Q4 2017, filed 9 Feb 2018.